Nav: Home

Current Immunotherapy News and Events

Current Immunotherapy News and Events, Immunotherapy News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Pioneering cell therapies for non-responders to current immunotherapies
Research led by VHIO's Alena Gros signposts a new, less invasive approach to identify killer T lymphocytes in patients with gastrointestinal tumors with low mutational burden who are refractory to approved immune-based treatments. (2019-10-16)
Yale scientists help immune system find hidden cancer cells
Cancer cells are masters at avoiding detection, but a new system developed by Yale scientists can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might miss, researchers report Oct. (2019-10-14)
Algorithm personalizes which cancer mutations are best targets for immunotherapy
As tumor cells multiply, they often spawn tens of thousands of genetic mutations. (2019-10-09)
Bioelectricity's promise for therapeutic targets in cancer
Bioelectricity of Cancer, a special issue of the peer-reviewed journal Bioelectricity, has just been published. (2019-10-09)
NUS scientist designs 'express courier service' for immune cells
Dr Andy Tay, a researcher with the National University of Singapore (NUS) who is currently doing his post-doctoral training at Stanford University, has successfully invented a novel transfection method to deliver DNA into immune cells with minimal stress on these cells. (2019-10-04)
The 'Goldilocks' principle for curing brain cancer
University of Minnesota Medical School researchers found that a stable body temperature holds the key to awakening the body's immune response to fight off brain cancer. (2019-10-04)
Engineered T cells may be harnessed to kill solid tumor cells
A new Tel Aviv University study finds that a form of immunotherapy used to treat the blood cancer leukemia may be effective in treating other kinds of cancer as well. (2019-10-02)
Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates
A combination of 2 immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust. (2019-09-28)
Tasmanian devil research could help tackle immunotherapy resistance
A cluster of interacting proteins that are active in both human cancers and Tasmanian devil facial tumours, may give clues to how cancers evade the immune system, according to a study part-funded by Cancer Research UK and published in Cancer Cell today (Thursday). (2019-09-26)
PACIFIC survival explained: Cancer spread reduced, new distant growth most often in the brain
A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. (2019-09-26)
Adding radiation after immunotherapy improves PFS for some pts with metastatic NSCLC
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer (NSCLC), increasing progression-free survival (PFS). (2019-09-26)
Resistance to immune checkpoint blocker drug linked to metabolic imbalance
A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute. (2019-09-25)
First CAR T cell therapy targeting B cell-activating factor receptor eradicates blood cancers
The first CAR T cell therapy targeting the B cell-activating factor receptor on cancerous cells eradicated CD19-targeted therapy-resistant human leukemia and lymphoma cells in animal models, according to City of Hope research published today in Science Translational Medicine. (2019-09-25)
Cancer protocols: A new approach to predicting treatment outcomes
Weizmann Institute of Science research shows heterogeneity in melanoma tumors prevents effective immune responses. (2019-09-23)
Electronic nose can sniff out which lung cancer patients will respond to immunotherapy
An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to immunotherapy, according to new research published in the leading cancer journal Annals of Oncology. (2019-09-17)
Subgroup of colorectal cancer patients ID'd: Do poorly, could benefit from immunotherapy
While the medical community agrees immune cells inside a tumor leads to improved health outcome, for a subset of colorectal cancer patients, having too much of a good thing is a strong predictor of disease recurrence and reduced chances of survival. (2019-09-16)
B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer. (2019-09-13)
Few people with peanut allergy tolerate peanut after stopping oral immunotherapy
Studies have shown that peanut oral immunotherapy (OIT) -- ingesting small, controlled amounts of peanut protein -- can desensitize adults and children and prevent allergic reactions, but the optimal duration and dose is unknown. (2019-09-12)
IMpower131
Patients with Stage IV squamous non-small cell lung cancer enrolled in clinical trial to test the immunotherapy atezolizumab and chemotherapy against chemotherapy alone experienced a longer survival rate, among a subgroup of patients with high PD-LI. (2019-09-10)
A liquid biopsy test can identify patients who may respond to immune checkpoint blockade
A new liquid biopsy test could detect microsatellite instability (MSI) and tumor mutational burden (TMB), indicating that it could help determine which patients are likely to respond to immune checkpoint inhibitors. (2019-09-10)
Durvalumab combined with chemotherapy improves overall survival in patients with lung cancer
Adding immunotherapy in the form of durvalumab to chemotherapy improves overall survival in patients with extensive-stage small cell lung cancer, according to research presented today at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC). (2019-09-09)
Protein mapping pinpoints why metastatic melanoma patients do not respond to immunotherapy
Tel Aviv University and Sheba Medical Center researchers say they have discovered why more than half of patients with metastatic melanoma do not respond to immunotherapy cancer treatments. (2019-09-09)
Preclinical study reveals the impact of age on immunotherapy treatment for breast cancer
In order to understand the influence of aging on the effectiveness of immune checkpoint blockade therapy, researchers from Brigham and Women's Hospital, the Dana Farber Cancer Institute, and Harvard Medical School conducted preclinical studies using younger and older mice with triple negative breast cancer, finding that age affects the efficacy of ICB therapy. (2019-09-06)
'Tiny fat bubbles' can boost immunity, calm disease
People living with inflammatory autoimmune disease could benefit from an 'immune system reboot', and researchers have isolated specific cells to target. (2019-09-05)
New peanut allergy treatment shows effectiveness and safety
Sublingual immunotherapy (SLIT) trial participants tolerated between 10 and 20 times more peanut protein than it would take for someone to get sick. (2019-09-04)
Discovered a factor that predicts long survival in brain tumor
Researchers of the Josep Carreras Leukaemia Research Institute have discovered an epigenetic lesion that allows identifying those patients affected by brain tumors that have a longer life expectancy. (2019-09-03)
Delivering immunotherapy directly to brain tumors
A new study published this week gives insight into how cancer immunotherapies might one day be delivered directly to the brain in order to treat brain tumors. (2019-08-29)
Researchers discover a new form of immunotherapy
A new form of immunotherapy that has so far been tested on mice makes it probable, that oncologists in the future may be able to treat some of the patients who are not responding to existing types of immunotherapy. (2019-08-27)
Cancer cells' immune weak spot revealed
Scientists have found a vulnerability in cancer cells that could make them more susceptible to being destroyed by the immune system, according to a new report in eLife. (2019-08-27)
Diverse immune cell profiles and roles found in breast cancer resistance to immunotherapy
Researchers show that heterogeneity of both breast cancer cells themselves and immune composition of the tumor microenvironment are important considerations for therapy. (2019-08-26)
Effectiveness of a new bladder cancer treatment demonstrated
Demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment. (2019-08-26)
Moffitt Researchers complete largest genomic analysis of Merkel cell carcinoma patients
Moffitt Cancer Center researchers have developed the largest descriptive genomic analysis of MCC patients to date, in collaboration with Foundation Medicine and the Dana Farber Cancer Institute. (2019-08-20)
A new path to cancer therapy: developing simultaneous multiplexed gene editing technology
Dr. Mihue Jang's group at the Korea Institute of Science and Technology(KIST) announced that they have developed a new gene editing system that could be used for anticancer immunotherapy through the simultaneous suppression of proteins that interfere with the immune system expressed on the surface of lymphoma cells and activation of cytotoxic T lymphocyte, based on the results of joint research conducted with Prof. (2019-08-20)
First clinical trial of drug-inducible gene therapy yields encouraging preliminary results
A new clinical trial by investigators from Brigham and Women's Hospital and Dana-Farber Cancer Institute set out to test the safety and effectiveness of controlling a powerful immunotherapy, known as human interleukin-12 (hIL-12), by using an oral activator -- a drug that can give finer control over when a gene gets turned on -- in patients with recurrent glioblastoma. (2019-08-14)
Manipulating dose, timing of two therapies reduces relapse in mouse models of breast cancer
Changing the standard dose and timing of two therapies greatly cut tumor relapse and reduced side effects in mouse models of kinase mutated breast cancer and lung cancer, UT Southwestern Simmons Cancer Center researchers have found. (2019-08-09)
Better tools, better cancer immunotherapy
Researchers from DTU have developed an important new tool towards producing therapies for cancer patients using the patient's own cells. (2019-08-09)
Balance of 'stop' and 'go' signaling could be key to cancer immunotherapy response
A crucial signaling pathway that can tell the immune system to fight off cancer can also be co-opted by cancer cells to put the brakes on the immune system. (2019-08-08)
Study shows why a common form of immunotherapy fails, and suggests solution
New research has uncovered a mechanism thought to explain why some cancers don't respond to a widely used form of immunotherapy called checkpoint inhibitors' or anti-PD-1. (2019-08-05)
Tel Aviv university scientists develop novel nano-vaccine for melanoma
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. (2019-08-05)
MSI detection via liquid biopsy shows high concordance with results from tissue samples
Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly 1,000 patients. (2019-08-05)
Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...